Ischemia in Medical Technology

Screening for Ischemia in Asymptomatic Patients With Type 2 Diabetes: Five- Year Outcomes in the DIAD Study

... in patients with diabetes. Silent myocardial ischemia is common, and cardiac death or ... of CAD. Data from the Detection of ischemia in Asymptomatic Diabetics (DIAD) Study, presented ... Wackers will present this study, "Screening for ischemia in Asymptomatic Patients with Type 2 Diabetes: ...

Vical Licensee Sanofi-aventis Initiates Phase 3 Trial to Reduce Amputations

... . About Critical Limb ischemia Critical limb ischemia is a severe and costly condition. In the ... No disease-modifying therapy for critical limb ischemia is currently available. About Vical Vical ...

Schering-Plough Announces Results of the Early ACS Trial

... efficacy endpoint was a composite of death, (re)infarction (MI), recurrent ischemia requiring urgent revascularization, or thrombotic bailout through 96 ... endpoint was a composite of all-cause mortality, (re)MI, recurrent ischemia requiring urgent revascularization, or thrombotic bailout through 96 ....

Prasugrel Significantly Reduced New or Recurrent Heart Attacks in Both Acute and Longer-Term Settings Following PCI, Compared with Clopidogrel

... P-LLY 1. Type 1: Spontaneous myocardial infarction related to ischemia due to a primary coronary event Type 2: Myocardial infarction secondary to ischemia due to either increased oxygen demand of the heart or decreased blood ...

CoAxia, Inc. Announces $21.5M Series D Financing

... is a venture-backed, privately held, clinical-stage company providing perfusion augmentation therapies to improve outcomes for patients with cerebral ischemia resulting from stroke, vasospasm and other conditions. In addition to the SENTIS, Flo24 and FASTFlo trials for ischemic stroke, CoAxia's NeuroFlo(TM) ...

Video: ev3 Inc. Announces First Patient Enrollments in DEFINITIVE LE Post-Market Study

... and Europe. The study will evaluate one-year patency in patients with leg pain (claudication) and one-year limb salvage in patients with critical leg ischemia (CLI) and include third party review of results by independent core-labs. "As one of the most robust plaque excision studies to date, ...

ThermoGenesis Announces MXP Involvement in New Regenerative Medicine Initiatives

... being conducted at the University of Naples in Italy to study the effect of bone marrow derived mononuclear cells on patients with critical limb ischemia (CLI). In addition, ThermoGenesis announced the launch of its distribution agreement with Celling Technologies, an orthopedics company focusing on ...

Palatin Technologies Presents PL-3994 Clinical Trial Results at the 12th Annual Scientific Meeting of the Heart Failure Association of America

... this system may have the potential to treat a variety of conditions and diseases, including sexual dysfunction, obesity and related disorders, ischemia and reperfusion injury, hemorrhagic shock and inflammation-related diseases. The natriuretic peptide receptor system has numerous cardiovascular ...

What is the Optimal Method of Ischemia Evaluation in WomeN: Preliminary Data from the WOMEN Study

... Major adverse cardiac events will be evaluated at one and two years. Dr. Gary Heller will present this study, "What Is the Optimal Method for ischemia Evaluation in Women: Preliminary Data from the WOMENs Trial" Saturday, September 13, 2008 at 10:50 a.m. in Room 306. The American Society of ...

Cardium Reports on Second Quarter 2008 Highlights and Financial Results

... to patients, caregivers and physicians. The AWARE study is evaluating the therapeutic effects of Generx for the potential treatment of myocardial ischemia (insufficient blood flow within the heart muscle) and associated angina due to coronary heart disease. Recruiting AWARE clinical study sites and ...

Data Presented at Annual Meeting of Japanese Society of Interventional Cardiology Demonstrate OrbusNeich's Genous(TM) Bio-engineered R Stent(TM) Has Better Outcomes When Compared to Drug-Eluting Stents

... major noncardiac surgery (NCS) or endovascular aortic repair (EVAR), underwent coronary angiography for clinical or instrumental signs of ischemia before NCS or EVAR and were treated with the Genous stent. Antiplatelet therapy was stopped five days prior to scheduled surgery in all patients, ...

Prescient Medical, Inc. Achieves Successful Clinical Debut of vProtect(TM) Luminal Shield

... in three patients with coronary artery disease DOYLESTOWN, Pa., May 29 /PRNewswire/ -- Three patients with established cardiac ischemia recently became the first recipients of the vProtect Luminal Shield, a self-expanding intracoronary prosthesis designed to limit arterial injury that ...

Ikaria Completes Dosing of Phase 1a Clinical Study for IK-1001 (Sodium Sulfide) for Injection

... in a variety of disease models including myocardial infarction, cardiopulmonary bypass surgery, thoracoabdominal aortic aneurysm surgery, liver ischemia and reperfusion, organ storage and transplantation and acute lung injury. Mark Roth, Ph.D., a member of the research faculty of the ...

PRoFESS(R) Results Announced at XVII European Stroke Conference

... 25mg / 200mg capsules combine a low dose of aspirin and extended-release dipyridamole to reduce the risk of stroke in patients who have had transient ischemia of the brain or completed ischemic stroke due to thrombosis. AGGRENOX is the only combination drug that has shown superiority to low-dose aspirin in ...

Northfield Laboratories Inc. Presentation at FDA/NIH Workshop on Hemoglobin-Based Oxygen Carriers

... (31%) Absent MI 83 (24%) 64 (18%) "This is useful information, which confirms the difficulty of diagnosing cardiac ischemia in trauma patients," said Dr. Gould. Dr. Gould concluded his presentation by summarizing the development of PolyHeme(R). "We believe our studies ...

Cardium's Innercool Therapies Unit Announces Publication of Positive Effects of Early and Rapid Hypothermia Following Heart Attack

... up to 50% of the final infarct size. Reperfusion injury refers to damage to tissue caused when blood supply returns to the tissue after a period of ischemia such as during blockage of the coronary arteries. The temporary absence of oxygen and nutrients from blood creates a condition in which the ...

Clinical Update - Debio 0614 (Istaroxime) in Acute Heart Failure

... properties. Its innovative mechanism of action allows for improving systolic and diastolic functions without causing significant arrhythmias or ischemia or increasing of myocardial oxygen consumption," said Kamel Besseghir, CEO of Debiopharm S.A. "Compared to available inotropes, known to be ...

CoAxia(TM) Announces $11.5M Equity Financing From Existing Investors

... privately held, development-stage company focused on providing perfusion augmentation therapies that improve outcomes for patients with cerebral ischemia resulting from stroke, vasospasm and other conditions. ...

CV Therapeutics' Anti-Ischemic Therapy Ranexa(R) Significantly Reduces Cardiac Chest Pain Symptoms and Recurrent Ischemia in MERLIN-TIMI 36 Patients With Angina

... Sessions of the American College of Cardiology shows that Ranexa(R) (ranolazine extended release tablets) significantly reduced the risk of recurrent ischemia (p=0.002), worsening angina (p=0.048) and intensification of antianginal therapy (p=0.009) in angina patients (n=3,565) in the MERLIN- TIMI 36 ...

Sangart, Inc. Initiates Dosing in Phase II Study of Hemospan(R) in Chronic Critical Limb Ischemia

... agents, announced today that it has started testing its lead product, Hemospan(R), in a Phase II clinical study involving chronic critical limb ischemia (CCLI) patients. The single-blind, placebo-controlled study at the Karolinska Institute in Stockholm, Sweden is designed to evaluate the safety and ...

Cytokine Announces Oral Efficacy of Anti-Cytokine Semapimod

... semapimod's efficacy in animal models of inflammatory and proliferative diseases, including endotoxic shock and toxicity, pancreatitis, ischemia and stroke, necrotizing enterocolitis, and neointimal formation. Despite early signals of efficacy, the Phase II studies CPSI conducted in Crohn's ...

Plavix(R) Indications Expanded in Japan to Include Patients with Acute Coronary Syndrome for Whom Percutaneous Coronary Intervention Is Being Planned

... ST elevation in ECG), and acute myocardial infarction are considered to be the series of the pathological condition referred to as acute myocardial ischemia as the clinical syndrome. These three symptoms and sudden cardiac death are collectively referred to as acute coronary syndrome. Immediate treatment ...

Studies Suggest Key Correlation Between Lung Cancer Subtype and Treatment Outcomes

... (8%); leukopenia (5%); neutropenia (5%); thrombocytopenia (2%); infection without neutropenia (6%); fatigue (16%); thrombosis/embolism (3%); cardiac ischemia (3%); anorexia (5%); dyspnea (18%); and chest pain (7%). The most common clinically relevant adverse events (all grades) were fatigue (87%); anorexia ...

TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)

... foot infection patients in a double-blind phase 2 trial. The company has first-in-class phase 1-ready drug candidates for treating critical limb ischemia and retinopathy/age-related macular degeneracy, and advanced preclinical candidates for chronic Hepatitis C virus infection and cancer. Contact ...

Acuity One-Year Findings Meet All Primary Endpoints in Favor of Angiomax (Bivalirudin) Alone Treatment Group

... previous findings, which showed similar ischemia at 30 days, and nearly 50% fewer episodes of ... alone treatment group, and * Composite ischemia events occurred in 16.4%, 16.5% and 16.3% of patients. Composite ischemia was defined as death, heart attack or ...

Inotek Pharmaceuticals Announces Publication of Animal Data from Study of PARP Inhibition as Potential Preventative of Brain Injury Following Stroke

... PARP inhibitor, PJ34, in a rat model of cerebral ischemia-reperfusion. ischemia is a restriction in blood supply to a tissue, whereas reperfusion injury ... is returned to that tissue. Rats were subjected to 10 minutes of cerebral ischemia and then treated with PJ34 or placebo (saline) for seven days beginning ...

Vical Licensee AnGes MG Announces Positive Results of Phase 3 Angiogenesis Trial in Japan

... blood flow). In the trial, 40 subjects with critical limb ischemia (advanced peripheral arterial disease) were evaluated for efficacy. The ... analysis of the PIII data using HGF Gene (AMG 0001) for Critical Limb ischemia (CLI) in Japan, and is pleased to announce that remarkable improvement was ...

Nuvelo Announces Publication of Phase 2 rNAPc2 Study Results in Journal of American College of Cardiology

... anticoagulant protein c2 (rNAPc2) reduced the incidence and duration of ischemia as measured by 7-day continuous electrocardiogram (ECG) by more than 50% ... "In the ANTHEM/TIMI 32 trial, the ability of higher-dose rNAPc2 to reduce ischemia in patients that are already receiving antithrombotic therapy is very ...

Abbott to Present New Data Across its Vascular Portfolio at the American College of Cardiology's 56th Annual Scientific Session

... The primary endpoint of the trial is in-segment late loss at 240 days. The major secondary endpoint of the randomized portion of the trial is ischemia driven target vessel failure at 270 days. The results from SPIRIT III are intended to support approval of the XIENCE V Stent System by the U.S. ...

Study: Identical Doses of BiDil Components Are Not Bioequivalent to the Fixed Dose Combination-BiDil-Used in A-HeFT

... BiDil should be used with caution in volume depleted or hypotensive patients. Hydralazine can cause tachycardia potentially leading to myocardial ischemia and anginal attacks. Careful clinical and hemodynamic monitoring is recommended when BiDil is administered to patients with acute myocardial ...

Indivumed Study Provides Sound Scientific Basis for a Predictive Drug Test- Platform

... oncological hospitals in the Hamburg metropolitan area. Indivumed's current tumor biobank of over 6000 patient-cases, collected with a mean cold ischemia time of less than eight minutes, serves as a resource for Indivumed's cancer research in primary cells and biomarkers as well as for the use ...

Northfield Laboratories Reports Results of Pivotal Phase III Trauma Study

... an accurate diagnosis of MI in trauma patients for multiple reasons, including direct trauma to the chest. Myocardial infarction and myocardial ischemia are traditionally assessed by EKGs and the cardiac enzymes Troponin I and CK-MB, both of which can be altered by direct trauma. Approximately 75% of ...

Ontak (denileukin diftitox) Achieves 49.1% Overall Response Rate in Phase III Trial of Cutaneous T-Cell Lymphoma (CTCL)

... (3%), fever (3%), hypoalbuminemia (2%), skin disorder (2%), chest pain (2%), vascular fragility (2%), fatigue (2%), hypersensitivity (2%), myocardial ischemia (1%), urinary tract infection (1%), blood pressure decreased (1%), joint stiffness (1%), myalgia (1%), carpel tunnel syndrome (1%), loss ...

Insmed Inc. Welcomes Studies Linking IGFBP-3 to Prevention of Blindness in Premature Infants

... important in the fight against ROP, but it also suggests promising avenues for research into the treatment of other conditions associated with ischemia and vascular damage." About IPLEX(TM) and ROP IPLEX(TM) is currently in the first phase of clinical development for the treatment of ROP, a ...

Beike Biotechnology Study Suggests Adult Stem Cells Show Promise for Peripheral Vascular Disease

... of cardiovascular disease in the elderly. A second study was completed during the same period comparing the relative improvement of lower limb ischemia (lack of blood supply) between transplantation of autologous peripheral blood stem cells and transplantation of bone marrow stem cells. The study ...

Nuvelo Announces Presentations on rNAPc2 and NU172 at the XXIst Congress of the International Society on Thrombosis and Haemostasis

... are as follows: Date/Time: Sunday, July 8, 2007, 5:30 p.m. CEST Poster Session (P-S-016): Tissue Factor/Factor VIIa Inhibitor Reduces ischemia in Patients with NSTE-ACS: Final Results of the ANTHEM-TIMI 32 Trial Date/Time: Sunday, July 8, 2007, 5:30 p.m. CEST Poster ...